Centogene NV (CNTG) 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Receives Nasdaq Non-Compliance Notice

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V...

CENTOGENE Explores Strategic Alternatives

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq:...